<?xml version="1.0" encoding="UTF-8"?>
<p id="para500">However, the limitations of our study also need to be acknowledged. Firstly, and most importantly, as the trial closed early to recruitment it was not adequately powered to assess the primary study endpoint. Another potential limitation of the study is in the interpretation of dose intensity for GEM-P; this regimen was administered weekly for 3 weeks out of 4, with the dose adjusted on each day of treatment in accordance with the blood counts on the day of treatment, which is in contrast to CHOP where treatment is administered once every 3 weeks allowing more time for count recovery.</p>
